DNAtriX
DNAtriX is a Houston-based clinical-stage biotechnology company developing an oncolytic virus platform to treat malignant glioma. Founded in 2005, it has raised approximately $57M in venture funding led by Morningside and DFJ Mercury to advance its engineered virus immunotherapy.
- Company typePrivate
- Founded2005
- HeadquartersHouston, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
DNAtriX firmographics
Firmographics- Name
- DNAtriX
- Website
- https://dnatrix.com
- Company type
- Private
- Founded year
- 2005
- Headcount range
- 11–50 employees
- Short description
- DNAtriX is a Houston-based clinical-stage biotechnology company developing an oncolytic virus platform to treat malignant glioma. Founded in 2005, it has raised approximately $57M in venture funding led by Morningside and DFJ Mercury to advance its engineered virus immunotherapy.
- Ownership category
- akta.pro rank
DNAtriX industry classification
Industry- Product category
- Oncolytic Virotherapy / Oncology Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF)
- akta.pro secondary industries
- Neuro-Oncology (HLAKAFAH), Medical Oncology (HLAKAFAB), Neuro-oncology (HLAKAIAL)
Keywords
Where DNAtriX is headquartered
LocationHeadquarters
- HQ city
- Houston
- HQ country
- United States
- HQ region
- North America
Markets served
DNAtriX business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Others
DNAtriX product offering
Product offeringCore offering
DNAtriX is a biotechnology company developing an oncolytic virus platform for treating malignant glioma. The platform uses tumor-selective viruses designed to infect and destroy cancer cells in the brain while sparing healthy tissue, addressing a high-need oncology indication with limited current treatment options.
Differentiator
Problem solved
Functional benefit
Products and services
- DNAtriX Oncolytic Virus Platform (malignant glioma program)
Companies that use DNAtriX
Customer profileIdeal customer profiles1 record
DNAtriX technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
DNAtriX competitors and assessment
Company assessmentDirect peers
- Replimune: Replimune is a clinical-stage biotech developing a proprietary oncolytic virus platform (RP1, RP2, RP3) for solid tumors. Like DNAtriX, it builds tumor-selective oncolytic immunotherapies, advancing them both as monotherapy and in combination with checkpoint inhibitors - the most direct strategic comparable in the space.
- Candel Therapeutics: Candel Therapeutics (formerly Advantagene) develops oncolytic virus and gene-mediated immunotherapy platforms including CAN-2409 for brain tumors and prostate cancer. It is one of the closest US-based clinical-stage competitors to DNAtriX in the glioma oncolytic virus space.
- Tocagen (now Kite/Gilead): Tocagen developed Toca 511/Toca FC, a retroviral replicating vector for high-grade glioma, before being acquired by Kite/Gilead. It is the most direct historical precedent for an oncolytic/replicating virus approach specifically targeting malignant glioma.
- Mustang Bio: Mustang Bio develops MB-101 (IL13Ralpha2-targeted CAR-T) and other cell/gene therapies for glioblastoma and other CNS malignancies. It represents a peer gene-therapy-for-glioma strategy, addressing the same indication using a different modality.
- Plus Therapeutics: Plus Therapeutics develops targeted radiotherapeutics for CNS cancers including glioblastoma (Rhenium-186 NanoLiposome). It is an indirect clinical-stage peer competing for the same malignant glioma treatment paradigm with non-oncolytic modality.
Broad incumbents
- Novocure: Novocure commercializes Tumor Treating Fields (Optune) as the standard-of-care adjunct for newly diagnosed and recurrent glioblastoma. It is the dominant incumbent in malignant glioma treatment and represents both the competitive benchmark and the combination-therapy partner universe for DNAtriX.
- Sorrento Therapeutics: Sorrento has multiple oncology franchises including oncolytic virus, antibody, and cell therapy assets touching glioma and solid tumors. It operates as a broader incumbent in the oncology gene and viral therapy space rather than a focused oncolytic virus pure-play.
Emerging players
- Oncorus: Oncorus is an early-stage biotech developing intratumorally administered oncolytic virus therapies (ONCR-177) leveraging synthetic biology. It is a meaningful emerging peer in the engineered oncolytic virus modality despite having a broader tumor-type focus than DNAtriX.
- Aettis Therapeutics: Aettis is a private early-stage biotech developing oncolytic virus and immuno-oncology approaches. It is a smaller, niche emerging peer in the same modality with limited but partial overlap with DNAtriX's viral immunotherapy approach.
- Ziopharm Oncology (now Alaunos Therapeutics): Alaunos Therapeutics (formerly Ziopharm Oncology) is a clinical-stage gene and cell therapy company with a Sleeping Beauty transposon platform that has historically engaged in glioma trials. It represents an emerging peer at the intersection of gene therapy and CNS oncology.
Market position
Customer concentration
DNAtriX social profiles
Digital presenceDNAtriX financial estimates
Financial estimateRevenue estimate
Valuation estimate
DNAtriX leadership team
Management profileNumber of profiles
Profiles8 records
DNAtriX funding detail
Funding detailFunding overview
Funding rounds13 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
DNAtriX M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about DNAtriX
What does DNAtriX do?
DNAtriX is a biotechnology company developing an oncolytic virus platform for treating malignant glioma. The platform uses tumor-selective viruses designed to infect and destroy cancer cells in the brain while sparing healthy tissue, addressing a high-need oncology indication with limited current treatment options.
When was DNAtriX founded?
DNAtriX was founded in 2005. It employs 11 to 50 people.
Where is DNAtriX based?
DNAtriX is headquartered in Houston, United States, in the North America region.
Who are DNAtriX's main competitors?
Direct peers on record are Replimune, Candel Therapeutics, Tocagen (now Kite/Gilead), Mustang Bio and Plus Therapeutics. Broad incumbents are Novocure and Sorrento Therapeutics. Emerging players are Oncorus, Aettis Therapeutics and Ziopharm Oncology (now Alaunos Therapeutics).
Does DNAtriX have an API?
No public API is recorded for DNAtriX.
What industry is DNAtriX in?
DNAtriX's product category is Oncolytic Virotherapy / Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAACAF, Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches), with a secondary code of HLAKAFAH, Neuro-Oncology. Its NAICS code is 541714 and its SIC code is 8731.